Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Balu

Showing results (1-10 of 76) with videos related to

Pageof 8
Sort By:
JAMA|November 30, 1979
Cardiac arrest following fluorescein angiographyE E Cunningham, V Balu
Archives of Dermatology|November 1, 1982
Self-inflicted anonychiaP T Hurley, V Balu
Methods in Molecular Biology (Clifton, N.J.)|February 15, 2011
In vitro immunogenicity risk assessment of therapeutic proteins in preclinical settingPuneet Gaitonde, Sathy V Balu-Iyer
Journal of Pharmaceutical Sciences|January 2, 2019
Immunogenicity of Protein PharmaceuticalsRobert Dingman, Sathy V Balu-Iyer
Journal of Pharmaceutical Sciences|July 20, 2016
Effect of Biophysical Properties of Phosphatidylserine Particle on Immune Tolerance Induction Toward Factor VIII in a Hemophilia A Mouse ModelRadha Ramakrishnan, Sathy V Balu-Iyer
Journal of Pharmaceutical Sciences|January 17, 2018
Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic ProteinsMichael R Turner, Sathy V Balu-Iyer
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 1, 2021
Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic ProteinsNicole L Jarvi, Sathy V Balu-Iyer
Thrombosis and Haemostasis|September 15, 2010
Phospholipid binding improves plasma survival of factor VIIIDipak S Pisal, Sathy V Balu-Iyer
Journal of Pharmaceutical Sciences|November 21, 2014
Anatomical, physiological, and experimental factors affecting the bioavailability of sc-administered large biotherapeuticsAnas M Fathallah, Sathy V Balu-Iyer
Journal of Pharmaceutical Sciences|August 5, 2016
Phosphatidylserine Converts Immunogenic Recombinant Human Acid Alpha-Glucosidase to a Tolerogenic Form in a Mouse Model of Pompe DiseaseJennifer L Schneider, Sathy V Balu-Iyer
Pageof 8

Showing results (1-10 of 76) with videos related to

Sort By:
Pageof 8
JAMA|November 30, 1979
Cardiac arrest following fluorescein angiographyE E Cunningham, V Balu
Archives of Dermatology|November 1, 1982
Self-inflicted anonychiaP T Hurley, V Balu
Methods in Molecular Biology (Clifton, N.J.)|February 15, 2011
In vitro immunogenicity risk assessment of therapeutic proteins in preclinical settingPuneet Gaitonde, Sathy V Balu-Iyer
Journal of Pharmaceutical Sciences|January 2, 2019
Immunogenicity of Protein PharmaceuticalsRobert Dingman, Sathy V Balu-Iyer
Journal of Pharmaceutical Sciences|July 20, 2016
Effect of Biophysical Properties of Phosphatidylserine Particle on Immune Tolerance Induction Toward Factor VIII in a Hemophilia A Mouse ModelRadha Ramakrishnan, Sathy V Balu-Iyer
Journal of Pharmaceutical Sciences|January 17, 2018
Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic ProteinsMichael R Turner, Sathy V Balu-Iyer
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 1, 2021
Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic ProteinsNicole L Jarvi, Sathy V Balu-Iyer
Thrombosis and Haemostasis|September 15, 2010
Phospholipid binding improves plasma survival of factor VIIIDipak S Pisal, Sathy V Balu-Iyer
Journal of Pharmaceutical Sciences|November 21, 2014
Anatomical, physiological, and experimental factors affecting the bioavailability of sc-administered large biotherapeuticsAnas M Fathallah, Sathy V Balu-Iyer
Journal of Pharmaceutical Sciences|August 5, 2016
Phosphatidylserine Converts Immunogenic Recombinant Human Acid Alpha-Glucosidase to a Tolerogenic Form in a Mouse Model of Pompe DiseaseJennifer L Schneider, Sathy V Balu-Iyer
Pageof 8